Published by Josh White on 28th October 2024
(Sharecast News) - BioVentix, a UK-based developer of high-affinity monoclonal antibodies for clinical diagnostics, reported a 6% improvement in full-year revenue on Monday, to £13.6m, up from £12.82m in the prior year.
URL: http://www.digitallook.com/dl/news/story/34651131/...